Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States-Reference-Cited by-同舟云学术

Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States

Published:2021-02 Issue:2 Volume:99 Page:115172
ISSN:0732-8893
Container-title:Diagnostic Microbiology and Infectious Disease
language:en
Short-container-title:Diagnostic Microbiology and Infectious Disease

Author:

Puzniak Laura,DePestel Daryl D.,Yu Kalvin,Ye Gang,Gupta Vikas

Funder

Merck Sharp and Dohme

Meso Scale Diagnostics

Publisher

Elsevier BV

Subject

Infectious Diseases,Microbiology (medical),General Medicine

Reference40 articles.

1. Ability of an antibiogram to predict Pseudomonas aeruginosa susceptibility to targeted antimicrobials based on hospital day of isolation;Anderson;Infect Control Hosp Epidemiol,2012

2. Carbapenem-nonsusceptible Pseudomonas aeruginosa isolates from intensive care units in the United States: a potential role for new β-lactam combination agents;Asempa;J Clin Microbiol,2019

3. How to manage Pseudomonas aeruginosa infections;Bassetti;Drugs Context,2018

4. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America;Boucher;Clin Infect Dis,2009

5. Meropenem and piperacillin/tazobactam prescribing in critically ill patients: does augmented renal clearance affect pharmacokinetic/pharmacodynamic target attainment when extended infusions are used?;Carlier;Crit Care,2013

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world evaluation of imipenem/cilastatin/relebactam across US medical centres;Journal of Global Antimicrobial Resistance;2024-06

2. Perspectives on the use of ceftolozane/tazobactam: a review of clinical trial data and real-world evidence;Future Microbiology;2024-01-22

3. Microevolution of Pseudomonas aeruginosa in the airways of people with cystic fibrosis;Current Opinion in Immunology;2023-08

4. Participant- and Disease-Related Factors as Independent Predictors of Treatment Outcomes in the RESTORE-IMI 2 Clinical Trial: A Multivariable Regression Analysis;Open Forum Infectious Diseases;2023-05-04

5. PSEUDOMONAS AERUGINOSA İZOLATLARININ ANTİBİYOTİK DİRENCİ VE YILLAR İÇİNDEKİ DEĞİŞİMİ;ANKEM Dergisi;2022-04-30